Abstract 10541: Improved Benefit Risk Profile of Rivaroxaban in a MARINER-Like Subpopulation of the MAGELLaN Study
Circulation(2018)
摘要
Introduction: The MAGELLaN Study was a randomized double-blind active (enoxaparin) and placebo controlled study of rivaroxaban (10mg QD) in medically ill hospitalized subjects treated in hospital a...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要